Twist Bioscience Form 4 Filings

Twist Bioscience Corp (TWST) reported a small insider transaction by its Senior Vice President of Human Resources, Paula Green. On 11/21/2025, Green sold 598 shares of common stock at a price of $26.5035 per share. After this transaction, she beneficially owned 167,789 shares directly.

The company explains that the sale was made to cover tax withholding obligations triggered by the vesting of Restricted Stock Units. These transactions are described as mandated under Twist Bioscience’s equity incentive plans through a “sell to cover” election, meaning they are not discretionary trades initiated by the executive for portfolio reasons.

Twist Bioscience Corporation's Chief Financial Officer reported an automatic sale of company stock to cover taxes. On 11/21/2025, the reporting person sold 887 shares of common stock at a price of $26.5035 per share. The filing explains that these shares were sold under a mandatory "sell to cover" arrangement tied to the vesting of Restricted Stock Units, meaning the transaction was not a discretionary trade. After this tax-related sale, the officer beneficially owned 142,769 shares of Twist Bioscience common stock in direct ownership.

Twist Bioscience Corp (TWST) reported an insider transaction by its Chief Executive Officer and director, Emily M. Leproust. On 11/21/2025, she disposed of 2,663 shares of common stock at a price of $26.5035 per share in a sale coded "S." This sale was made to cover tax withholding obligations triggered by the vesting of restricted stock units, and is described as a mandatory "sell to cover" under the company’s equity incentive plans rather than a discretionary trade.

Following this transaction, Leproust beneficially owned 878,173 shares of common stock, held directly. She also holds several employee stock options with various exercise prices and vesting schedules, including performance stock options granted on September 1, 2020 that vested and became exercisable on December 19, 2022 after meeting specified performance criteria.

Twist Bioscience Corp (TWST) reported insider share sales by its Chief Accounting Officer. The reporting person sold 229 shares of common stock on 11/21/2025 at a price of $26.5035 per share and 822 shares on 11/24/2025 at a price of $28.7095 per share. After these transactions, the officer beneficially owned 66,143 shares of Twist Bioscience common stock in direct ownership.

According to the explanation, the 229 and 822 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, and the sales did not represent discretionary trades by the officer.

Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of $0 per share, increasing her directly held beneficial ownership to 880,836 common shares.

The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to continued service. The filing also lists multiple outstanding employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85, covering hundreds of thousands of shares with expiration dates between 2027 and 2030. Some older options at $5.95 now show zero remaining shares.

Twist Bioscience Corp (TWST) reported a routine insider equity grant to its President and COO, Patrick John Finn. On 11/18/2025, he received 68,740 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share. Following this grant, he beneficially owned 334,659 shares of Twist Bioscience common stock in total.

The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, subject to his continued service. This structure ties a portion of the executive’s compensation to the company’s long-term performance and his ongoing role.

Twist Bioscience Corp (TWST) reported that its Chief Financial Officer received a grant of 32,648 restricted stock units (RSUs) of common stock on 11/18/2025. The RSUs were recorded at a price of $0 because they are equity awards rather than open‑market purchases.

Following this grant, the CFO beneficially owns 143,656 shares of Twist Bioscience common stock in total. The RSU award vests over four years: 1/16 of the total RSUs vest on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, as long as the executive remains in continuous service through each vesting date.

Twist Bioscience Corp (TWST) officer Dennis Cho reported a grant of 25,465 restricted stock units (RSUs) of common stock at a price of $0 per share. After this equity award, he beneficially owns 146,159 shares of Twist Bioscience common stock in total.

The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, subject to his continuous service with the company. Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and this Form 4 reflects routine insider equity compensation.

Twist Bioscience Corp. (TWST) reported an equity award to a senior executive. Officer Paula Green, the company’s SVP of Human Resources, received 26,200 shares of common stock in the form of a restricted stock unit (RSU) grant on 11/18/2025 at a stated price of $0, reflecting a compensatory award rather than an open‑market purchase.

The RSUs vest over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to her continued service through each vesting date. Following this grant, Paula Green beneficially owns 168,387 shares of Twist Bioscience common stock, held directly.

Twist Bioscience Corp (TWST) reported a Form 4 for its Chief Accounting Officer, Robert F. Werner. On 11/18/2025, he received 16,324 shares of common stock through a restricted stock unit (RSU) award at a price of $0 per share, reflecting stock-based compensation rather than a market purchase.

After this grant, Werner beneficially owns 67,194 shares of Twist Bioscience common stock in direct ownership. The RSU award vests over time: 1/16 of the RSUs vest on each quarterly anniversary of November 20, 2024, for a total vesting period of 48 months, contingent on his continued service with the company.

Twist Bioscience Corp (TWST) director Jan Johannessen reported a stock sale in a Form 4 filing. On 11/18/2025, the reporting person sold 7,044 shares of Twist Bioscience common stock at a price of $24.77 per share, coded as a sale transaction ("S"). After this transaction, the director beneficially owned 14,859 shares of common stock in the company, held directly. The filing is made as an individual filing by one reporting person and is signed by an attorney-in-fact on behalf of Jan Johannessen.

Twist Bioscience (TWST) insider Dennis Cho reported a sale of 1,019 shares of common stock at $32.0794 on 11/03/2025. According to the filing, this was a mandated “sell to cover” tied to the vesting of Restricted Stock Units to satisfy tax withholding obligations, not a discretionary trade. Following the transaction, Cho beneficially owns 120,694 shares, held directly. His role is listed as Senior Vice President, Chief Legal Officer & Corporate Secretary.

Twist Bioscience Corp (TWST) reported an insider transaction by President and COO Patrick John Finn. On 11/03/2025, he disposed of 2,755 shares of common stock at a price of $32.0794 per share.

The filing states these shares were sold to satisfy tax withholding obligations related to the vesting of Restricted Stock Units under the company’s equity incentive plans, a mandated “sell to cover” and not a discretionary trade by the reporting person. Following the transaction, he directly beneficially owned 265,919 shares.

Twist Bioscience (TWST) insider Paula Green, SVP of Human Resources, reported a transaction on 11/03/2025. She sold 1,084 shares of common stock at $32.0794 per share. According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon the vesting of Restricted Stock Units and did not represent a discretionary trade. Following the transaction, she beneficially owns 142,187 shares directly.

Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a Form 4 transaction: she sold 4,887 shares of common stock on 11/03/2025 at $32.0794 per share.

According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon RSU vesting, and not a discretionary trade. Following the transaction, she beneficially owns 733,922 shares directly.

She also holds employee stock options, including 266,539 at $26.66 expiring 11/18/2028 and 150,879 at $8.82 expiring 09/28/2027.

Twist Bioscience (TWST) disclosed an insider transaction by its Chief Accounting Officer, Robert F. Werner. On 11/03/2025, he sold 160 shares of common stock at $32.0794 in a mandated sell-to-cover to satisfy tax withholding arising from the vesting of restricted stock units under the company’s equity plan. Following the transaction, his beneficial ownership stood at 50,870 shares.

Twist Bioscience (TWST) filed a Form 4 reporting an insider tax-related sale. On 10/30/2025, a company officer executed a mandated "sell-to-cover" of 6,515 shares of common stock at $31.4443 per share to satisfy tax withholding tied to the vesting of Performance Stock Units. The filing notes these were not discretionary trades.

Following the transaction, the reporting person directly owned 121,713 shares. The insider is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary.

Twist Bioscience (TWST) reported an insider transaction by President and COO Patrick John Finn. On 10/30/2025, he sold 17,606 shares of common stock at $31.4443 per share, coded “S.” The filing states these shares were sold solely to cover tax withholding triggered by the vesting of Performance Stock Units under a mandated “sell to cover” election in the company’s equity plans, indicating they were not discretionary trades.

Following the transaction, Finn beneficially owns 268,674 shares, held directly.

Twist Bioscience (TWST) reported an insider transaction by its SVP of Human Resources, Paula Green. On 10/30/2025, she sold 6,920 shares of common stock (transaction code S) at $31.4443 per share. The filing states these shares were sold to satisfy tax withholding obligations from vesting Performance Stock Units via a mandated “sell to cover,” indicating they were not discretionary trades. Following the transaction, she beneficially owned 143,271 shares, held directly.

Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a transaction on 10/30/2025: the disposition of 31,379 shares of common stock at $31.4443 per share. The filing states these shares were sold to cover tax withholding tied to the vesting of performance stock units, pursuant to the company’s equity plan “sell to cover” election, and were not discretionary trades.

Following the transaction, Leproust beneficially owns 738,809 common shares directly. Derivative holdings listed include employee stock options, such as 150,879 options at an exercise price of $8.82 and 266,539 options at $26.66, among others with varying vesting and expiration terms.

Twist Bioscience (TWST) reported an insider transaction by its Chief Financial Officer, Adam Laponis. On 10/30/2025, the CFO sold 5,517 shares of common stock at $31.4443 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Performance Stock Units and were executed as a mandated “sell to cover,” not a discretionary trade.

Following the transaction, the reporting person beneficially owns 111,008 shares directly.

Twist Bioscience (TWST) insider transaction: the Chief Accounting Officer reported a sale of 1,016 shares of common stock on 10/30/2025 at a price of $31.4443 per share. The filing states the sale was a mandated “sell to cover” to satisfy tax withholding obligations tied to the vesting of Performance Stock Units, and not a discretionary trade. Following the transaction, the reporting person beneficially owned 51,030 shares, held directly.

Twist Bioscience (TWST): insider equity award update. President and COO Patrick John Finn acquired 79,785 shares of common stock at $0 on October 28, 2025, recorded as an “A” (acquisition). Following this transaction, he beneficially owns 286,280 shares directly. The shares reflect Performance Stock Units for which target criteria were determined to have been met on October 28, 2025. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration as provided in the award agreement.

Twist Bioscience (TWST): Form 4 insider update. Company officer Dennis Cho reported acquisition of 29,518 shares of common stock on 10/28/2025 at a price of $0, reflecting Performance Stock Units (PSUs) with target criteria determined to be met. Following this transaction, beneficial ownership stands at 128,228 shares, held directly.

The filing notes that 60% of these PSUs remain subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent on continued service or potential acceleration under the award agreement. Role: Senior Vice President, Chief Legal Officer & Corporate Secretary.

Twist Bioscience (TWST) reported an insider equity award. The company’s SVP of Human Resources acquired 35,513 shares of common stock at $0 on October 28, 2025, tied to Performance Stock Units whose target criteria were met.

Following the transaction, the reporting person beneficially owns 150,191 shares. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, contingent on continued service or acceleration as provided in the agreement.

Twist Bioscience (TWST) reported an insider equity award for its CEO and director, Emily M. Leproust. On 10/28/2025, she acquired 168,976 shares of common stock at $0, tied to Performance Stock Units whose target criteria were determined to have been met. The filing notes that 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement.

Following the transaction, Leproust beneficially owns 770,188 shares directly. The filing also lists existing employee stock options, including grants with exercise prices of $8.82, $26.66, $23.33, and $67.85, with various vesting and expiration terms as disclosed.

Twist Bioscience (TWST) reported an equity award to its Chief Accounting Officer, Robert F. Werner. A Form 4 shows an acquisition of 5,633 shares at $0 on October 28, 2025, tied to performance stock units where target criteria were met.

According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement. Following the transaction, beneficial ownership stands at 52,046 shares, held directly.

Twist Bioscience (TWST) reported an insider equity award. CFO Adam Laponis acquired 25,000 shares of common stock at $0 on October 28, 2025, tied to performance stock units whose target criteria were determined to have been met on that date.

After the transaction, he beneficially owned 116,525 shares, held directly. Per the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or potential acceleration under the agreement.

Twist Bioscience (TWST) disclosed a Form 4 for its President and COO, Patrick John Finn. On 10/23/2025, he sold 2,240 shares of common stock at $30.875 per share.

The filing explains the sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting of Restricted Stock Units, and it does not represent discretionary trading. After this transaction, Finn beneficially owned 206,495 shares, held directly.

Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis reported two planned equity sales under Rule 10b5-1 and company tax-withholding procedures. On 10/08/2025 he sold 3,000 shares at $31.15 under a pre-established trading plan adopted on 05/08/2025. On 10/09/2025 he sold 2,517 shares at $32.922 to satisfy tax withholding for vested restricted stock units; the filing notes these "sell to cover" sales are mandatory under the equity incentive plan and not discretionary. Following these transactions he beneficially owned 91,525 shares.

Twist Bioscience Corp (TWST) chief financial officer Adam Laponis sold shares to cover tax withholding tied to vested performance stock units. On 10/06/2025 the filing shows a sale of 5,875 shares at $32.187 per share as a mandatory "sell to cover" for tax obligations. After the sale the reporting person beneficially owned 97,042 shares. The form clarifies these were not discretionary trades but sales required under the company's equity plan to satisfy withholding.

Insider sale to cover tax withholding following PSU vesting. The Form 4 shows Twist Bioscience Corp (TWST) Chief Executive Officer and Director Emily M. Leproust reported a sale of 31,348 shares on 10/06/2025 at a price of $32.187 per share. The filing states the sale was a mandated "sell to cover" to satisfy tax-withholding obligations tied to vesting Performance Stock Units, not a discretionary trade. After the transaction, the Reporting Person beneficially owns 601,212 shares and holds multiple outstanding employee stock options totaling reported option counts, including 64,950 exercisable shares from a performance grant.

Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 2,041 shares of common stock on 10/06/2025 at a price of $32.187 per share. After the sale, Mr. Werner beneficially owned 46,413 shares. The filing states the shares were sold to satisfy tax-withholding obligations tied to the vesting of Performance Stock Units (PSUs) and were executed under the issuer's mandatory "sell to cover" election, not as voluntary open-market trades. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp (TWST), reported a non‑discretionary sale of 9,724 common shares on 10/06/2025 at an effective price of $32.187 per share to satisfy tax withholding tied to vested Performance Stock Units (PSUs).

After the sell‑to‑cover, the reporting person beneficially owns 114,678 shares. The filing was submitted under Form 4 and signed by an attorney‑in‑fact on 10/08/2025. The sale was mandated by the issuer's equity plan election and is described as not a discretionary trade.

Insider sale to cover taxes: The Form 4 shows that Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), had 23,747 shares of common stock sold on 10/06/2025 at $32.187 per share. The filing states these sales were mandatory "sell to cover" transactions to meet tax‑withholding obligations tied to vested Performance Stock Units (PSUs) and were not discretionary trades. After the transaction, the reporting person beneficially owned 208,735 shares. The sale was reported on 10/08/2025 and signed by an attorney‑in‑fact.

Twist Bioscience Corp (TWST) reported an insider sale by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On 10/06/2025 Mr. Cho sold 3,876 shares of common stock at a price of $32.187 per share to satisfy tax withholding tied to the vesting of Performance Stock Units (PSUs). After the transaction he beneficially owned 98,710 shares. The filing notes these were mandatory "sell to cover" transactions elected under the company equity plans and are not discretionary trades by the reporting person.

Dennis Cho, Senior Vice President and Chief Legal Officer of Twist Bioscience Corporation (TWST), reported a sale of 124 shares of Common Stock on 10/02/2025. The transaction is described as a sell-to-cover executed to satisfy tax withholding on vested restricted stock units rather than a discretionary sale. The reported sale price was $29.161 per share and the reporting person retained 102,586 shares after the transaction. The form is signed by an attorney-in-fact and discloses the reporter's officer role.

Paula Green, who serves as SVP of Human Resources and a director at Twist Bioscience Corp (TWST), reported a mandated sell-to-cover transaction tied to the vesting of restricted stock units. On 10/02/2025 she disposed of 140 shares of common stock at $29.161 per share to satisfy tax withholding, leaving her with 124,402 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 10/06/2025.

The filing explicitly states the sale was not a discretionary trade but a company-mandated sale under the issuer's equity plan to cover tax obligations arising from RSU vesting. No options, warrants, or other derivative transactions are reported on this form.

Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corporation (TWST), reported a small non-discretionary sale of shares to cover tax withholding related to vested restricted stock units. The filing shows a sale of $29.161 per share for 476 shares on 10/02/2025, described as a mandatory "sell to cover" to satisfy tax withholding; these sales were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 632,560 shares of common stock.

The Form 4 also lists outstanding employee stock options and performance options with various exercise prices and vesting/exercise dates, including options exercisable immediately and a granted performance option that vested on 12/19/2022. The report was signed by an attorney-in-fact on 10/06/2025.

Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a sale of $29.161-priced common stock on 10/02/2025. The Form 4 shows 206 shares were sold to satisfy tax withholding obligations tied to vested Restricted Stock Units; the filing states these were mandatory 'sell to cover' transactions rather than discretionary trades. Following the transaction and an administrative correction, the reporting person beneficially owns 232,482 shares. The Form 4 was filed by counsel on 10/06/2025 and is signed by an attorney-in-fact.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale on 09/22/2025 to satisfy tax withholding for vested restricted stock units. The filing shows 233 shares disposed at $27.56 per share and the reporting person held 102,710 shares following the transaction. The sale is described as a company-mandated "sell to cover" tied to equity plan withholding, not a voluntary trade by the insider.

The Form 4 was signed on 09/24/2025 by an attorney-in-fact. No other transactions or derivative positions are reported in this filing.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of 295 shares of TWST common stock on 09/22/2025 at an average price of $27.56 per share, leaving her with 124,542 shares beneficially owned. The filing indicates the sale was a mandatory "sell to cover" transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units rather than a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact and submitted on 09/24/2025. The transaction is routine for equity compensation settlements and does not, by itself, indicate a change in officer ownership intent.

Emily M. Leproust, CEO and Director of Twist Bioscience (TWST), reported a non-discretionary sale and her current holdings. The filing shows a sale of 1,704 shares of Twist common stock on 09/22/2025 at $27.56 per share performed to satisfy tax-withholding required under the company's equity plans. After that transaction she beneficially owns 633,036 shares directly. The form also lists outstanding employee stock options with exercise prices and post-transaction holdings: $5.95 (0), $8.82 (150,879), $26.66 (266,539), $23.33 (131,290) and $67.85 (64,950). The filing notes one set of performance stock options vested and became exercisable on 12/19/2022.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 09/15/2025 to satisfy tax withholding tied to vested restricted stock units. The reported transaction lists a price of $25.328 per share and shows 102,943 shares beneficially owned by the reporting person after the transaction. The filing was signed by an attorney-in-fact on 09/17/2025. The form states the sale was a mandated "sell to cover" required by the issuer's equity incentive plan and not a discretionary trade by the reporting person.